Eagle Pharmaceuticals Stock Buy Hold or Sell Recommendation
| EGRX Stock | USD 4.19 0.10 2.44% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Eagle Pharmaceuticals is 'Strong Sell'. Macroaxis provides Eagle Pharmaceuticals buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding EGRX positions. The advice algorithm takes into account all of Eagle Pharmaceuticals' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Eagle Pharmaceuticals' buy or sell advice are summarized below:
Real Value 7.33 | Target Price 17 | Hype Value 4.03 | Market Value 4.19 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Eagle Pharmaceuticals given historical horizon and risk tolerance towards Eagle Pharmaceuticals. When Macroaxis issues a 'buy' or 'sell' recommendation for Eagle Pharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
Eagle |
Execute Eagle Pharmaceuticals Buy or Sell Advice
The Eagle recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Eagle Pharmaceuticals. Macroaxis does not own or have any residual interests in Eagle Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Eagle Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very Small | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Eagle Pharmaceuticals Trading Alerts and Improvement Suggestions
| Eagle Pharmaceuticals generated a negative expected return over the last 90 days | |
| Eagle Pharmaceuticals has high historical volatility and very poor performance | |
| Eagle Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
| Over 87.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Eagle Pharmaceuticals Announces a Trial in Progress Presentation of Phase 23 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients at the Upcoming Society for Ambulatory Anesthesia 2024 Annual Meeting |
Eagle Pharmaceuticals Returns Distribution Density
The distribution of Eagle Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Eagle Pharmaceuticals' future price movements. The chart of the probability distribution of Eagle Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Eagle Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Eagle Pharmaceuticals returns is essential to provide solid investment advice for Eagle Pharmaceuticals.
| Mean Return | -0.29 | Value At Risk | -7.92 | Potential Upside | 8.00 | Standard Deviation | 5.17 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Eagle Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Eagle Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Eagle Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Eagle Pharmaceuticals backward and forwards among themselves. Eagle Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Eagle Pharmaceuticals' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Acadian Asset Management Llc | 2023-12-31 | 287.6 K | Dimensional Fund Advisors, Inc. | 2023-12-31 | 246.5 K | J. Goldman & Co Lp | 2023-12-31 | 246.4 K | Geode Capital Management, Llc | 2023-12-31 | 225.3 K | State Street Corporation | 2023-12-31 | 222.6 K | Two Sigma Advisers, Llc | 2023-12-31 | 222 K | Assenagon Asset Management Sa | 2023-12-31 | 217.7 K | Two Sigma Investments Llc | 2023-12-31 | 207.6 K | Bank Of America Corp | 2023-12-31 | 187 K | Blackrock Inc | 2023-12-31 | 984.9 K | Hhg Plc | 2023-12-31 | 775.5 K |
Eagle Pharmaceuticals Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | 1.7M | (1.5M) | (13.8M) | (8.3M) | (7.5M) | (7.1M) | |
| Change In Cash | 31.0M | (6.6M) | (5.5M) | (42.3M) | (38.1M) | (36.2M) | |
| Free Cash Flow | 55.2M | 48.8M | 27.9M | 50.5M | 58.1M | 61.0M | |
| Depreciation | 4.7M | 4.8M | 3.8M | 12.0M | 13.8M | 14.5M | |
| Other Non Cash Items | 480K | 8.7M | 7.6M | 11.3M | 13.0M | 13.7M | |
| Capital Expenditures | 777K | 747K | 323K | 178K | 160.2K | 152.2K | |
| Net Income | 14.3M | 12.0M | (8.6M) | 35.6M | 41.0M | 43.0M | |
| End Period Cash Flow | 109.8M | 103.2M | 97.7M | 55.3M | 63.6M | 73.0M | |
| Investments | (777K) | (18.2M) | (5.3M) | (86.8M) | (78.1M) | (74.2M) | |
| Change Receivables | 18.5M | (3.1M) | 9.5M | (30.8M) | (35.5M) | (33.7M) | |
| Net Borrowings | (6.3M) | (5M) | (8M) | 11.4M | 10.3M | 16.2M | |
| Change To Netincome | 22.2M | 28.5M | 21.4M | 17.7M | 20.4M | 16.0M |
Eagle Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Eagle Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Eagle Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Eagle stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.36 | |
β | Beta against NYSE Composite | 1.20 | |
σ | Overall volatility | 5.22 | |
Ir | Information ratio | -0.07 |
Eagle Pharmaceuticals Volatility Alert
Eagle Pharmaceuticals exhibits very low volatility with skewness of 0.25 and kurtosis of 0.11. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Eagle Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Eagle Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Eagle Pharmaceuticals Fundamentals Vs Peers
Comparing Eagle Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Eagle Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Eagle Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Eagle Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Eagle Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Eagle Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Eagle Pharmaceuticals to competition |
| Fundamentals | Eagle Pharmaceuticals | Peer Average |
| Return On Equity | 0.0488 | -0.31 |
| Return On Asset | 0.0663 | -0.14 |
| Profit Margin | 0.05 % | (1.27) % |
| Operating Margin | 0.16 % | (5.51) % |
| Current Valuation | 110.22 M | 16.62 B |
| Shares Outstanding | 12.96 M | 571.82 M |
| Shares Owned By Insiders | 12.02 % | 10.09 % |
| Shares Owned By Institutions | 87.22 % | 39.21 % |
| Number Of Shares Shorted | 1.18 M | 4.71 M |
| Price To Earning | 40.52 X | 28.72 X |
| Price To Book | 0.24 X | 9.51 X |
| Price To Sales | 0.23 X | 11.42 X |
| Revenue | 316.61 M | 9.43 B |
| Gross Profit | 221.67 M | 27.38 B |
| EBITDA | 65.48 M | 3.9 B |
| Net Income | 35.64 M | 570.98 M |
| Cash And Equivalents | 36.56 M | 2.7 B |
| Cash Per Share | 2.75 X | 5.01 X |
| Total Debt | 62.47 M | 5.32 B |
| Debt To Equity | 0.23 % | 48.70 % |
| Current Ratio | 1.78 X | 2.16 X |
| Book Value Per Share | 19.25 X | 1.93 K |
| Cash Flow From Operations | 50.7 M | 971.22 M |
| Short Ratio | 7.01 X | 4.00 X |
| Earnings Per Share | 0.85 X | 3.12 X |
| Price To Earnings To Growth | 0.91 X | 4.89 X |
| Target Price | 17.0 | |
| Number Of Employees | 134 | 18.84 K |
| Beta | 0.41 | -0.15 |
| Market Capitalization | 53 M | 19.03 B |
| Total Asset | 406.16 M | 29.47 B |
| Retained Earnings | 111.5 M | 9.33 B |
| Working Capital | 77.67 M | 1.48 B |
Note: Disposition of 735 shares by Brian Cahill of Eagle Pharmaceuticals at 5.13 subject to Rule 16b-3 [view details]
Eagle Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Eagle . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Daily Balance Of Power | 9.2 T | |||
| Rate Of Daily Change | 1.02 | |||
| Day Median Price | 4.19 | |||
| Day Typical Price | 4.19 | |||
| Price Action Indicator | 0.05 | |||
| Period Momentum Indicator | 0.1 |
About Eagle Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Eagle Pharmaceuticals? Buying financial instruments such as Eagle Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 25.6M | 62.5M | 71.8M | 41.6M | Total Assets | 253.7M | 406.2M | 467.1M | 490.4M |
Use Investing Ideas to Build Portfolios
In addition to having Eagle Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Military Industrial Thematic Idea Now
Military Industrial
A collection of large United States defense contractors including companies involved in production or distribution of aircraft, ships, vehicles, weaponry, and electronic systems in cooperation with the government. The Military Industrial theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Military Industrial Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Eagle Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Eagle Stock please use our How to Invest in Eagle Pharmaceuticals guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for Eagle Stock analysis
When running Eagle Pharmaceuticals' price analysis, check to measure Eagle Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eagle Pharmaceuticals is operating at the current time. Most of Eagle Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eagle Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eagle Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eagle Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |
Is Eagle Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eagle Pharmaceuticals. If investors know Eagle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eagle Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.87) | Earnings Share 0.85 | Revenue Per Share 19.684 | Quarterly Revenue Growth (0.13) | Return On Assets 0.0663 |
The market value of Eagle Pharmaceuticals is measured differently than its book value, which is the value of Eagle that is recorded on the company's balance sheet. Investors also form their own opinion of Eagle Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eagle Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eagle Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eagle Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eagle Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eagle Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eagle Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.